Loading... Please wait...

Our Newsletter

GDC-0879 | B-Raf inhibitor

  • GDC-0879.jpg
  • GDC-0879, 400x400px, png
Catalog #:

Product Description

GDC0879 is highly selective, orally-bioavailable, oxime-containing pyrazole type inhibitor of B-Raf (V600E) kinase with a potency of 0.13 nM. [1] In a screening of a panel of kinases at 1 uM activity only RAF kinases were shown to have >90% inhibition, with only one additional kinase (casein kinase 1-delta) at >50% inhibition. [2] GDC0879 effectively reduces pERK levels at 63 nM and cellular viability of B-Raf mutant MALME3M cells at 0.75 uM. [2]

In A375 melanoma and Colo205 colorectal carcinoma cell lines, GDC0879 exhibits dose-depdnent pMEK1 inhibition of 59 and 29 nM, respectively. No evidence of apoptotic activation pathways in vitro was observed, suggesting that GDC0879's antitumor activity is based primarily on its effect on cell proflieration. [1] Pathway modulation in A375 tumors was shown to be significant (13% and 28% activity remaining at 1 and 4 hours, respectively) by measuring MEK1 phoshporylation of Ser217/221. Reduced levels of pMEK1 were still evident at 8h post dose (59%), but returned to baseline at 12h. Similar studies in SK23 tumors did not display such a strong PD effect.

Technical information:

Chemical Formula:   C19H18N4O2
CAS #:   905281-76-7
Molecular Weight:   334.37
Purity:   > 98%
Appearance:   White
Chemical Name:   (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime
Solubility:   Up to 100 mM in DMSO
Synonyms:   GDC-0879, GDC 0879, GDC0879

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Wong et al., Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J. Pharm. Exp. Ther. 2009, 329(1), 360-367 Pubmed ID: 19147858
2. Hoeflich et al., Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009, 69(7), 3042-3051 Pubmed ID: 19276360

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the GDC-0879 | B-Raf inhibitor to your wish list.

You Recently Viewed...